Literature DB >> 25898174

Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment?

Diana Peiteado1, Alejandro Villalba1, Emilio Martín-Mola1, Eugenio de Miguel1.   

Abstract

OBJECTIVES: We undertook this study to evaluate the responsiveness of Doppler ultrasound (US) to urate lowering therapy (ULT) in gout patients.
METHODS: Twenty-four consecutive patients were prospectively included from an outpatient clinic. The patients underwent clinical, and US assessment at baseline and after 6, 12 and 24 months of ULT. The US assessment was made by another rheumatologist blinded to the clinical data. Standardised examinations were performed in four joints (both first metatarso-phalangeals and knees) and the patellar tendons. The Doppler signals were scored. The mean and standard deviation were calculated for each parameter. The comparison between the quantitative values was performed by Student's t-test. Sensitivity to change in the US examinations was assessed by estimating the smallest detectable difference (SDD) in the total Doppler score.
RESULTS: A Doppler signal was detected in 95.8% of the patients at the baseline. A significant parallel improvement in the serum urate level, clinical parameters and in Doppler scores was found at the follow-up assessment. 62% of the patients had achieved a uric concentration level below 6 mg/dl at one year. At two years, persistence of a Doppler signal was found in 72.7% of the patients. The SDD in the Doppler score at 2 years was 1.92, lower than the difference achieved.
CONCLUSIONS: The Doppler US findings show significant improvement and responsiveness after ULT in gout patients. The Doppler signal persistence after two years of treatment is marked. This finding introduces a reflection on the accuracy of the current outcome measures and treatments.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25898174

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Current status of ultrasound and dual-energy computed tomography in the evaluation of gout.

Authors:  Hillary W Garner; Daniel E Wessell
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

2.  Tendon involvement in patients with gout: an ultrasound study of prevalence.

Authors:  Lucio Ventura-Ríos; Guadalupe Sánchez-Bringas; Carlos Pineda; Cristina Hernández-Díaz; Anthony Reginato; Magaly Alva; Marcelo Audisio; Ana Bertoli; Tomas Cazenave; Marwin Gutiérrez; Claudia Mora; Guillermo Py; Oscar Sedano; Carla Solano; Eugenio de Miguel
Journal:  Clin Rheumatol       Date:  2016-05-28       Impact factor: 2.980

3.  Entheseal Involvement in Spondyloarthritis (SpA) and Gout: An Ultrasound Comparative Study.

Authors:  Lucio Ventura-Ríos; Tomas Cazenave; Cristina Hernández-Díaz; Selma Gallegos-Nava; Citlallyc Gómez-Ruiz; Marcos Rosemffet; Karina Silva-Luna; Pedro Rodríguez-Henríquez; Janitzia Vázquez-Mellado; Julio Casasola-Vargas; Esteban Cruz-Arenas; Eugenio M de Miguel
Journal:  Front Med (Lausanne)       Date:  2022-05-24

Review 4.  The Role of Advanced Imaging in Gout Management.

Authors:  Shuangshuang Li; Guanhua Xu; Junyu Liang; Liyan Wan; Heng Cao; Jin Lin
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

5.  Sonographic Tophi and Inflammation Are Associated With Carotid Atheroma Plaques in Gout.

Authors:  Irene Calabuig; Agustín Martínez-Sanchis; Mariano Andrés
Journal:  Front Med (Lausanne)       Date:  2021-12-16

6.  Influence of non-steroidal anti-inflammatory drugs on the inflammatory sonographic features in erosive hand osteoarthritis: an intervention study.

Authors:  Qun Xia Xu; Ruth Wittoek
Journal:  Rheumatol Adv Pract       Date:  2020-01-28

7.  Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy.

Authors:  Sara Nysom Christiansen; Mikkel Østergaard; Ole Slot; Helen Keen; George A W Bruyn; Maria Antonietta D'Agostino; Lene Terslev
Journal:  RMD Open       Date:  2020-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.